Cargo Therapeutics(CRGX.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Cargo Therapeutics
CRGX.US
CARGO Therapeutics, Inc., a clinical-stage biotechnology company, focused on designing, engineering, and developing potentially curative cell therapies for cancer patients in the United States. The company develops CRG-023, a tri-specific CAR T product candidate which is in phase 1 that targets tumor cells with three B-cell malignancies; and allogeneic platform, a universal vector solution designed to effectively limit immune-based rejection to enable durable response of CAR T-cell therapy. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc.
1.880 T
CRGX.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Shareholder Alert: The Ademi Firm Continues to Investigate Whether CARGO Therapeutics, Inc. is Obtaining a Fair Price for its Public Shareholders

    The Ademi Firm is investigating CARGO Therapeutics, Inc. (NASDAQ: CRGX) for potential breaches of fiduciary duty related to its transaction with Concentra Biosciences. Shareholders will receive $4.379 per share and a contingent value right. The investigation focuses on whether the CARGO board is acting in the best interest of shareholders, as the transaction limits competing offers and provides significant benefits to insiders. Interested parties can contact the firm for more information.

    MorningStar·
    US
    CRGX
    0.00%
    MorningStar·
    US
    CRGX
    0.00%

    Wall Street Zen Upgrades CARGO Therapeutics (NASDAQ:CRGX) to Sell

    Wall Street Zen has upgraded CARGO Therapeutics (NASDAQ:CRGX) to a "sell" rating in a recent research report. Jefferies Financial Group also raised its price target for the stock from $3.70 to $5.00, maintaining a "hold" rating. Currently, CARGO Therapeutics has a consensus rating of "Reduce" with an average price target of $15.40. The stock opened at $4.47, with a market cap of $216.17 million. Institutional investors hold 93.16% of the stock, indicating strong interest in the company.

    Market Beat·
    US
    CRGX
    0.00%
    Market Beat·
    US
    CRGX
    0.00%

    CARGO Therapeutics Acquired by Concentra Biosciences

    CARGO Therapeutics, Inc. has been acquired by Concentra Biosciences, resulting in CARGO becoming a wholly owned subsidiary. This merger led to the delisting of CARGO’s shares from Nasdaq and a filing for deregistration with the SEC. Analysts rate CRGX stock as a Hold with a $5.00 price target, but Spark's AI Analyst indicates it is an Underperform due to no revenue and increasing losses. The company faces financial distress, although potential future opportunities exist in CAR T therapy and partnerships.

    Tip Ranks·
    US
    CRGX
    0.00%
    Tip Ranks·
    US
    CRGX
    0.00%

    Cargo Therapeutics Announces Delisting from Nasdaq Following Merger Completion

    Cargo Therapeutics Inc. has announced its delisting from Nasdaq following its merger with Concentra Biosciences, LLC. The company has notified Nasdaq of the merger's completion and requested the suspension of trading of its shares, effective August 19, 2025. Additionally, Cargo Therapeutics has filed a Notification of Removal from Listing with the SEC to delist its shares and terminate its registration under the Securities Exchange Act of 1934, becoming a wholly owned subsidiary of Concentra Biosciences.

    Reuters·
    US
    CRGX
    0.00%
    Reuters·
    US
    CRGX
    0.00%

    CARGO Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

    CARGO Therapeutics Inc reported a quarterly adjusted loss of $1.04 per share for the quarter ended June 30, missing analyst expectations of a loss of 62 cents. The company had a total loss of $49.94 million, with reported revenue at zero. Despite an 8.7% rise in shares this quarter, they have lost 68.9% year-to-date. Analysts maintain a "hold" rating on the stock, with no revisions in earnings estimates over the past month. The average consensus for the biotechnology sector remains a "buy."

    Reuters·
    US
    CRGX
    0.00%
    Reuters·
    US
    CRGX
    0.00%
    © 2026 Longbridge｜Disclaimer